New drug combo shows promise in Hard-to-Treat breast cancer
NCT ID NCT02390427
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called taselisib combined with standard anti-HER2 therapies in 68 people with advanced HER2+ breast cancer. The goal was to find the safest dose and see if the combination could shrink tumors or slow the disease. While not a cure, the approach aims to better control cancer that has spread or come back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States